TY - JOUR
T1 - Recent treatments of interstitial lung disease with systemic sclerosis
AU - Yasuoka, Hidekata
N1 - Publisher Copyright:
© the authors, publisher and licensee Libertas Academica Limited.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2016/1/19
Y1 - 2016/1/19
N2 - Systemic sclerosis (SSc) is a disorder characterized by immune dysfunction, microvascular injury, and fibrosis. Organ involvement in patients with SSc is variable; however, pulmonary involvement occurs in up to 90% of patients with SSc. Interstitial lung disease (ILD) is a major cause of mortality and, thus, a major determinant in the prognosis of patients with SSc. This review summarizes current findings about the characteristics of ILD in patients with SSc, selection of patients with SSc-ILD who are candidates for the treatment, and current treatment options.
AB - Systemic sclerosis (SSc) is a disorder characterized by immune dysfunction, microvascular injury, and fibrosis. Organ involvement in patients with SSc is variable; however, pulmonary involvement occurs in up to 90% of patients with SSc. Interstitial lung disease (ILD) is a major cause of mortality and, thus, a major determinant in the prognosis of patients with SSc. This review summarizes current findings about the characteristics of ILD in patients with SSc, selection of patients with SSc-ILD who are candidates for the treatment, and current treatment options.
UR - http://www.scopus.com/inward/record.url?scp=84960345465&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960345465&partnerID=8YFLogxK
U2 - 10.4137/CCRPM.S23315
DO - 10.4137/CCRPM.S23315
M3 - Article
AN - SCOPUS:84960345465
VL - 9
SP - 97
EP - 110
JO - Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine
JF - Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine
SN - 1179-5484
ER -